Paper Details

  1. Home
  2. Paper Details

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

Author: AbadaPaolo, AlencarAlvaro J, BalbasMinna, BrownJennifer R, CheahChan Y, CohenJonathon B, CoombsCatherine C, EyreToby A, FakhriBita, FlinnIan W, GersonJames N, GhiaPaolo, Hernandez-IlizaliturriFrancisco, JagadeeshDeepa, JurczakWojciech, LamannaNicole, Lech-MarandaEwa, MaShuo, MatoAnthony R, MunirTalha, NairBinoj, PatelKrish, PatelManish R, RhodesJoanna M, RuppertAmy S, SeymourJohn F, ShahNirav N, TamConstantine S, TsaiDonald E, UjjaniChaitra S, WangChunxiao, WangDenise, WierdaWilliam G, WoyachJennifer A, ZinzaniPier L

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to reestablish BTK inhibition in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have had poor outcomes after treatment with covalent Bruton's tyrosine kinase (BTK) inhibitors.
Paper Details　
Original Abstract of the Article :
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2300696

データ提供：米国国立医学図書館（NLM）

Pirtobrutinib: A New Hope in the Desert of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL), a type of cancer affecting the blood and bone marrow, is a challenging disease to treat. This research explores the potential of pirtobrutinib, a noncovalent BTK inhibitor, as a therapeutic option for patients with CLL who have experienced resistance to prior treatment with covalent BTK inhibitors. The researchers aimed to evaluate the efficacy and safety of pirtobrutinib in this challenging patient population.

Pirtobrutinib: A New Oasis in the Desert of CLL Treatment

The study highlights the potential of pirtobrutinib as a promising new therapeutic option for patients with CLL who have failed prior treatment with covalent BTK inhibitors. The researchers found that pirtobrutinib demonstrated significant activity in this patient population, suggesting its potential to re-establish BTK inhibition and improve clinical outcomes.

Navigating the Desert of CLL Treatment: Seeking New Therapies

The study's findings provide a glimmer of hope for patients with CLL who have exhausted existing treatment options. Further research is needed to fully evaluate the long-term efficacy and safety of pirtobrutinib in this challenging patient population.

Dr.Camel's Conclusion

This research is a beacon of hope in the desert of CLL treatment, highlighting the potential of pirtobrutinib to provide a new path to remission for patients who have faced resistance to prior therapies. By exploring innovative treatment options and embracing new approaches, we can create a more fertile landscape for conquering this challenging disease.

Date :
  1. Date Completed 2023-07-16
  2. Date Revised 2023-07-18
Further Info :

Pubmed ID

37407001

DOI: Digital Object Identifier

10.1056/NEJMoa2300696

Related Literature

Article Analysis
・Effects of pirtobrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.